Tag
This community-engaged mixed-methods study identifies critical Return of Value (ROV) elements, such as genetic insights and community health benefits, to improve biobanking engagement among Black women with endometrial cancer, offering 14 a
A large-scale cohort study of premenopausal women demonstrates that adjuvant tamoxifen significantly increases the risk of endometrial cancer, hyperplasia, and polyps, with risk correlating to treatment duration.
A phase 2 trial demonstrates that combining letrozole, abemaciclib, and metformin achieves a 32% response rate and 60% clinical benefit rate in ER+ endometrioid endometrial cancer, with notable efficacy in CTNNB1-mutated tumors and an inter
Results from the UTOLA trial reveal that ESR1 mutations, a hallmark of AI resistance in breast cancer, are present in 22% of metastatic NSMP low-grade endometrial cancer patients before endocrine therapy, suggesting a need for molecular str
The PORTEC-4a trial confirms that molecular profiling safely guides adjuvant treatment in high-intermediate risk endometrial cancer, reducing overtreatment by 46% while maintaining non-inferiority in locoregional control compared to standar
A large-scale multicenter study indicates that cervical stromal invasion is not an independent prognostic factor for survival in early-stage endometrial cancer, challenging traditional staging assumptions when other high-risk features are c
The PORTEC-3 trial demonstrates that adding platinum-based chemotherapy to pelvic radiotherapy significantly improves 10-year overall and recurrence-free survival in high-risk endometrial cancer, especially in patients with p53 abnormal tum
The ENDOLA trial explored olaparib with metronomic cyclophosphamide and metformin, demonstrating a favorable safety profile and promising efficacy in heavily pretreated recurrent endometrial cancer patients, highlighting molecular subtype-d
This review synthesizes recent evidence on metformin’s therapeutic and prognostic roles in cervical, ovarian, and endometrial cancers, highlighting randomized trials, meta-analyses, and clinical outcomes with a focus on progression-fr
This phase II/III study assessed whether adding metformin to standard paclitaxel and carboplatin improved outcomes in advanced and recurrent endometrial cancer. The trial was stopped early due to lack of survival benefit and potential harm,
Fertility-preserving hormonal therapy for early-stage endometrial cancer shows comparable 5-year survival to hysterectomy in women under 40, but a significantly higher mortality risk in those aged 40-49 years, highlighting age as a critical
This analysis compares survival in young women with early-stage endometrial cancer treated with fertility-preserving hormonal therapy versus hysterectomy, highlighting survival equivalence in women under 40 years and increased mortality ris
This study compares ChatGPT-4o and gynecologic oncologists in addressing endometrial cancer patient questions, showing superior AI accuracy, empathy, and completeness, though lengthy responses may challenge patient comprehension.
